In recent years, a higher frequency of MET exon 14 splicing site mutations has been reported in PSC, with a prevalence ranging from 4.9% to 31.8%, compared to 2.62% in all NSCLC. The gene discussed is MET; the disease is non-small cell lung carcinoma.